BTCC / BTCC Square / Global Cryptocurrency /
Rani Therapeutics Stock Surges 150% on Oversubscribed Private Placement

Rani Therapeutics Stock Surges 150% on Oversubscribed Private Placement

Published:
2025-10-17 15:35:03
9
3
BTCCSquare news:

Rani Therapeutics (RANI) shares skyrocketed 150% in pre-market trading after announcing a $60.3 million private placement. The clinical-stage biotherapeutics company secured commitments from institutional investors, including Executive Chairman Mir Imran and new backer Samsara, at $0.48 per share.

The deal includes 42.6 million shares and 82.4 million pre-funded warrants, each carrying an additional five-year warrant. Proceeds will advance the company's RaniPill platform pipeline. This capital injection follows a 65% year-to-date decline for the stock, highlighting investor confidence in the company's turnaround potential.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.